Retreatment of hepatitis C — sofosbuvir/velpatasvir/ voxilaprevir (SOF/VEL/VOX) 1

In the RESOLVE study, 77 patients with hepatitis C who had
previously failed direct acting antiviral therapy (DAA) were
treated with SOF/VEL/VOX for 12 weeks.

Read more